Bordetella pertussis antigens encapsulated into N-trimethyl chitosan nanoparticulate systems as a novel intranasal pertussis vaccine
Source abstract
Abstract
The mucosal immune system serves as the first line of defense against Bordetella pertussis. Intranasal vaccination, due to its potential to induce systemic and mucosal immune responses, appears to prevent the initial adherence and colonization of the bacteria at the first point of contact. In the present study, two B. pertussis antigens, pertussis Toxoid (PTd) and Filamentous hemagglutinin (FHA), which play a very significant role in virulence and protection against pertussis, were encapsulate into N-trimethyl chitosan (TMC) nanoparticulate systems. After preparation of TMC nanoparticles (NPs), the NPs were characterized and their ability to induce efficient immune responses against B. pertussis was studied in a mouse model. Our findings showed that PTd + FHA-loaded TMC NPs have strong ability to induce IL-4, IL-17, IFN-γ, IgG, and IgA in the mouse model. Results from this study suggest that nasal administration of the PTd + FHA-loaded TMC NPs induced not only a systemic immune response but also a local mucosal response, which may improve the efficacy of pertussis prevention through respiratory tract transmission.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Bacterial Infections and Vaccines · Pneumonia and Respiratory Infections · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Medical Genetics, Shahid Sadoughi University of Medical Sciences
Department of Biotechnology, Razi Vaccine and Serum Research Institute (RVSRI)
Department of Nursing, School of Nursing, Larestan University of Medical Sciences
Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences
Molecular Biology Research Center, Baqiyatallah University of Medical Sciences
Funding
Shahid Sadoughi University of Medical Sciences and Health Services · Razi Vaccine and Serum Research Institute
References (46)
Show source-provided references
1. 10.1128/CMR.00083-1510.1128/CMR.00083-15 ↗
2. 10.1038/nrmicro323510.1038/nrmicro3235 ↗
3. 10.1146/annurev-micro-091014-10420910.1146/annurev-micro-091014-104209 ↗
4. 10.3389/fimmu.2018.0306810.3389/fimmu.2018.03068 ↗
5. 10.4161/hv.811210.4161/hv.8112 ↗
6. Storsaeter J, Wolter J, Locht C. Pertussis vaccines. In Locht C, editor. Bordetella molecular microbiology. Norfolk, UK: Horizon Press; 2007. p. 245–288.
7. 10.1007/5584_2016_2110.1007/5584_2016_21 ↗
8. 10.1586/14760584.6.1.4710.1586/14760584.6.1.47 ↗
9. 10.1111/j.1574-695X.2012.00988.x10.1111/j.1574-695X.2012.00988.x ↗
10. 10.1056/NEJMoa120085010.1056/NEJMoa1200850 ↗
11. 10.1073/pnas.131468811010.1073/pnas.1314688110 ↗
12. 10.1101/cshperspect.a02945410.1101/cshperspect.a029454 ↗
13. 10.1016/j.jinf.2016.04.02010.1016/j.jinf.2016.04.020 ↗
14. 10.1128/IAI.67.3.1056-1062.199910.1128/IAI.67.3.1056-1062.1999 ↗
15. 10.1128/IAI.67.3.1050-1055.199910.1128/IAI.67.3.1050-1055.1999 ↗
16. 10.1016/j.addr.2005.07.00910.1016/j.addr.2005.07.009 ↗
17. 10.1016/S0168-3659(02)00363-210.1016/S0168-3659(02)00363-2 ↗
18. 10.1016/j.ijpharm.2008.04.03610.1016/j.ijpharm.2008.04.036 ↗
19. 10.1007/12_2011_15010.1007/12_2011_150 ↗
20. 10.4155/tde-2016-006810.4155/tde-2016-0068 ↗
21. 10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-410.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4 ↗
22. 10.1016/j.vaccine.2010.06.12110.1016/j.vaccine.2010.06.121 ↗
23. 10.1016/0003-2697(85)90442-710.1016/0003-2697(85)90442-7 ↗
24. 10.1016/j.ijpharm.2006.11.02710.1016/j.ijpharm.2006.11.027 ↗
25. 10.1016/j.imlet.2018.03.01210.1016/j.imlet.2018.03.012 ↗
26. 10.1038/mi.2012.5410.1038/mi.2012.54 ↗
27. Ross PJ, Sutton CE, Higgins S, et al. Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine. PLoS One. 2013;9:e1003264.
28. 10.1038/s41385-018-0080-x10.1038/s41385-018-0080-x ↗
29. Mehrabi M, Montazeri H, Mohamadpour Dounighi N, et al. Chitosan-based nanoparticles in mucosal vaccine delivery. Arch Razi Inst. 2018;73:165–176.
30. 10.1517/17425247.2012.69745510.1517/17425247.2012.697455 ↗
31. 10.1016/j.jiec.2015.10.02810.1016/j.jiec.2015.10.028 ↗
32. 10.1016/j.biomaterials.2008.05.02610.1016/j.biomaterials.2008.05.026 ↗
33. 10.1016/j.ijpharm.2004.09.00210.1016/j.ijpharm.2004.09.002 ↗
34. 10.1016/S0264-410X(02)00435-810.1016/S0264-410X(02)00435-8 ↗
35. 10.1038/nri177710.1038/nri1777 ↗
36. 10.1016/j.ijbiomac.2015.11.01210.1016/j.ijbiomac.2015.11.012 ↗
37. 10.1016/j.jconrel.2009.05.01110.1016/j.jconrel.2009.05.011 ↗
38. 10.1016/j.vaccine.2006.06.08610.1016/j.vaccine.2006.06.086 ↗
39. 10.1016/j.vaccine.2018.02.07210.1016/j.vaccine.2018.02.072 ↗
40. 10.3109/21691401.2016.114673510.3109/21691401.2016.1146735 ↗
41. 10.1016/j.carbpol.2012.04.05610.1016/j.carbpol.2012.04.056 ↗
42. 10.1016/j.ijpharm.2010.08.02010.1016/j.ijpharm.2010.08.020 ↗
43. 10.1016/B978-0-323-39981-4.00015-410.1016/B978-0-323-39981-4.00015-4 ↗
44. 10.1128/IAI.69.8.4846-4850.200110.1128/IAI.69.8.4846-4850.2001 ↗
45. 10.1016/S0264-410X(98)00077-210.1016/S0264-410X(98)00077-2 ↗
46. 10.1016/0264-410X(95)00134-M10.1016/0264-410X(95)00134-M ↗